GALECTIN THERAPEUTICS INC.

GALT ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Income Statement
Annual Quarterly

Income Statement

Line Item FY2010
Revenue
Cost of Revenue
Gross Profit
Gross Margin
Operating Expenses
Research & Development $1.1M
SG&A Expense $3.8M
Operating Income $-4.9M
Operating Margin
Interest Expense
Pretax Income
Income Tax Expense
Net Income $-5.6M
Net Margin
EPS (Basic) $-0.93
EPS (Diluted) $-0.93
Shares Outstanding (Basic) 10.7M
Shares Outstanding (Diluted) 10.7M
Dividends Per Share
← Newer Page 3 of 3 Older →